Amar Safdar1, Kenneth V I Rolston. 1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. asafdar@mdanderson.org
Abstract
BACKGROUND: The clinical significance of infections caused by vancomycin-tolerant (Vt) gram-positive organisms in patients with cancer remains unclear. METHODS: Twenty-five patients with nonenterococcal gram-positive bloodstream infection, which was refractory to vancomycin therapy, were identified by reviewing the Infectious Diseases consultation database at the tertiary care cancer center. Among these, 8 patients in whom vancomycin-tolerance was documented are described. Antibiotic tolerance was defined as a > 32 times increase in minimum bactericidal concentration compared with minimum inhibitory concentration. RESULTS: Eight patients with persistent fever and bacteremia of > 72 hours' duration after the initiation of vancomycin therapy were treated. The median age of these patients, which included 3 men and 5 women, was 44 years +/- 11 years. Solid tumors were more common (6 patients) and 2 patients had acute leukemia. Six patients (75%) were neutropenic (absolute neutrophil count < 500/mm3), including 2 breast cancer patients who had undergone autologous stem cell transplantation. The causative organisms were Staphylococcus aureus (n = 3 patients), group G streptococci (n = 2 patients), and Staphylococcus epidermidis, Streptococcus mitis, and Streptococcus sanguis (1 patient each). All isolates demonstrated a minimum bactericidal concentration for vancomycin that was at least 32 times greater than the minimum inhibitory concentration. Rapid defervescence (< or = 24 h) and resolution of bacteremia occurred with the addition of gentamicin (4 patients) or gentamicin plus rifampin (4 patients). None of these infections recurred after discontinuation of therapy. CONCLUSIONS: Lack of clinical and/or microbiologic response to vancomycin should raise the suspicion of possible infection due to Vt gram-positive bacteria, and alternative bactericidal therapy should be instituted early, especially in patients with underlying immune suppression. 2006 American Cancer Society
BACKGROUND: The clinical significance of infections caused by vancomycin-tolerant (Vt) gram-positive organisms in patients with cancer remains unclear. METHODS: Twenty-five patients with nonenterococcal gram-positive bloodstream infection, which was refractory to vancomycin therapy, were identified by reviewing the Infectious Diseases consultation database at the tertiary care cancer center. Among these, 8 patients in whom vancomycin-tolerance was documented are described. Antibiotic tolerance was defined as a > 32 times increase in minimum bactericidal concentration compared with minimum inhibitory concentration. RESULTS: Eight patients with persistent fever and bacteremia of > 72 hours' duration after the initiation of vancomycin therapy were treated. The median age of these patients, which included 3 men and 5 women, was 44 years +/- 11 years. Solid tumors were more common (6 patients) and 2 patients had acute leukemia. Six patients (75%) were neutropenic (absolute neutrophil count < 500/mm3), including 2 breast cancerpatients who had undergone autologous stem cell transplantation. The causative organisms were Staphylococcus aureus (n = 3 patients), group G streptococci (n = 2 patients), and Staphylococcus epidermidis, Streptococcus mitis, and Streptococcus sanguis (1 patient each). All isolates demonstrated a minimum bactericidal concentration for vancomycin that was at least 32 times greater than the minimum inhibitory concentration. Rapid defervescence (< or = 24 h) and resolution of bacteremia occurred with the addition of gentamicin (4 patients) or gentamicin plus rifampin (4 patients). None of these infections recurred after discontinuation of therapy. CONCLUSIONS: Lack of clinical and/or microbiologic response to vancomycin should raise the suspicion of possible infection due to Vt gram-positive bacteria, and alternative bactericidal therapy should be instituted early, especially in patients with underlying immune suppression. 2006 American Cancer Society
Authors: Truc T Tran; Nagendra N Mishra; Ravin Seepersaud; Lorena Diaz; Rafael Rios; An Q Dinh; Cristina Garcia-de-la-Maria; Michael J Rybak; Jose M Miro; Samuel A Shelburne; Paul M Sullam; Arnold S Bayer; Cesar A Arias Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: C Garcia-de-la-Maria; Y Q Xiong; J M Pericas; Y Armero; A Moreno; N N Mishra; M J Rybak; T T Tran; C A Arias; P M Sullam; A S Bayer; J M Miro Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown Journal: Antimicrob Agents Chemother Date: 2009-02-17 Impact factor: 5.191
Authors: Brianne Zapata; Danya N Alvarez; Sabrina Farah; Cristina Garcia-de-la-Maria; Jose M Miro; George Sakoulas; Arnold S Bayer; Nagendra N Mishra Journal: Curr Microbiol Date: 2018-04-12 Impact factor: 2.188
Authors: Juwon Yim; Jordan R Smith; Nivedita B Singh; Seth Rice; Kyle Stamper; Cristina Garcia de la Maria; Arnold S Bayer; Nagendra N Mishra; José M Miró; Truc T Tran; Cesar A Arias; Paul Sullam; Michael J Rybak Journal: J Antimicrob Chemother Date: 2017-08-01 Impact factor: 5.790
Authors: Kenneth V I Rolston; Weiqun Wang; Lior Nesher; Samuel A Shelburne; Randall A Prince Journal: J Antibiot (Tokyo) Date: 2015-12-02 Impact factor: 2.649
Authors: Nagendra N Mishra; Truc T Tran; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Kym Faull; Alex Yoon; Richard Proctor; Jose M Miro; Michael J Rybak; Arnold S Bayer; Cesar A Arias; Paul M Sullam Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941